I don't recall this being posted, so I apologize i

I don't recall this being posted, so I apologize if it has. CytoDyn has updated it FAQ web page.

https://www.cytodyn.com/investors/investor-faqs

Here is the first two FAQs for quick reference:

FREQUENTLY ASKED QUESTIONS

Last updated March 2025

What are the 2025 clinical objectives of the Company?

i. Continue the pending Phase II trial of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer;

ii. Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including but not limited to metastatic Triple-Negative Breast Cancer; and

iii. Continue our work researching and developing a new or modified long-acting version of leronlimab.

The Company will also strategically work with select partners to explore leronlimab’s potential benefits in certain inflammatory diseases.

What is the current status of the longer-acting therapeutic project?

In order to develop a long-acting therapeutic, we have partnered with an experienced drug development company that uses generative artificial intelligence (AI), among other technologies, in its development activities. If successful, such a modified therapeutic would require less frequent injections for patients on drug, furthering the convenience and overall marketability of the product. Working with a company with established AI-capabilities allows for a robust development path for this modified, longer-acting therapeutic for the Company. This joint development initiative remains in progress at this time and the Company will provide further updates when appropriate.